Back to Agenda
Session 6: FDA's Actions on the Original IND and Future Amendments
Session Chair(s)
Elliott Berger, PHD, MS
President
ETB Regulatory Consulting, United States
- FDA’s Review of an IND
- Clinical Holds: Basis for Imposition and Process for Removal
Have an account?